01:40:56 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-06 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning EXPRS2 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-16 Kvartalsrapport 2024-Q1
2024-02-08 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-25 Ordinarie utdelning EXPRS2 0.00 SEK
2023-05-24 Årsstämma 2023
2023-05-16 Kvartalsrapport 2023-Q1
2023-03-23 Extra Bolagsstämma 2023
2023-02-09 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-27 Ordinarie utdelning EXPRS2 0.00 SEK
2022-05-25 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning EXPRS2 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-09-23 Extra Bolagsstämma 2020
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning EXPRS2 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-24 Ordinarie utdelning EXPRS2 0.00 SEK
2019-05-23 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-25 Ordinarie utdelning EXPRS2 0.00 SEK
2018-05-24 Årsstämma 2018
2018-05-17 Kvartalsrapport 2018-Q1
2018-02-07 Bokslutskommuniké 2017
2017-11-30 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-06-01 Ordinarie utdelning EXPRS2 0.00 SEK
2017-05-31 Årsstämma 2017
2017-05-24 Kvartalsrapport 2017-Q1
2017-04-19 Extra Bolagsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-08 Kvartalsrapport 2016-Q3
2016-08-31 Kvartalsrapport 2016-Q2

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
ExpreS2ion Biotech Holding är ett forsknings- och utvecklingsbaserat bolag som har en patenterad plattform inom bioteknisk proteinproduktion. Bolaget har sin egen utvecklingspipeline av vaccinkandidater inom COVID-19, bröstcancer, influensa och malaria. Dessutom har bolaget intäkter från försäljning av tillverkningstjänster och plattformslicenser. Bolaget startade 2010 och har sin verksamhet i DTU Forskerpark i Hørsholm.
2022-04-07 13:00:00

Hørsholm, Denmark, April 7, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the World Vaccine Congress (April 18-21), a Q&A session covering the 2022 Rights Issue (April 25), Økonomisk Ugebrev Life Science Investor Conference (April 27), PEGS Summit (May 2-6), and the ESMO Breast Cancer Meeting (May 3-5).

By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS[2] technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below.

World Vaccine Congress, April 18-21
Washington, D.C., USA
Meet in-person with ExpreS[2]ion's CMO, Mattis Flyvholm Ranthe at the largest, most established meeting dedicated to vaccines. More information and registration can be found on the World Vaccine Congress website (https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm).

2022 Rights Issue Q&A hosted by H.C. Andersen Capital, April 25 at 11:00 CET
Virtual
ExpreS[2]ion CEO Bent U. Frandsen and CFO Keith Alexander will discuss the 2022 Rights Issue and answer investor's questions about how to participate. More information and registration can be found on the H.C. Andersen Capital events website (https://hcandersencapital.dk/events/) closer to the webcast.

Økonomisk Ugebrev Life Science Investor Conference, April 27 at 15:50-16:20 CET
Copenhagen, Denmark
See the company presentation by our CEO Bent U. Frandsen at this investor event. It is possible to attend the meeting by reserving a seat on the event website (https://www.eventbrite.co.uk/e/life-science-investor-konference-den-27-april-2022-tickets-296710217247?aff=odeimcmailchimp&utm_source=Marketing&utm_campaign=bb056e5d1f-EMAIL_CAMPAIGN_2019_08_20_07_22_COPY_01&utm_medium=email&utm_term=0_32a4ba3d31-bb056e5d1f-108505633&mc_cid=bb056e5d1f&mc_eid=f12ce3e69b).

PEGS Summit, May 2-6
Boston, MA, USA
Meet virtually with ExpreS[2]ion's VP of R&D and Technology, Max Søgaard, at the leading international meeting for the biotherapeutics community. More information and registration can be found on the PEGS Summit website (https://www.pegsummit.com/).

European Society for Medical Oncology (ESMO) Breast Cancer Meeting, May 3-5
Berlin, Germany and Virtual
Meet with ExpreS[2]ion's CMO, Mattis Flyvholm Ranthe, and VP of Preclinical Development, Mette Thorn, at 2022 ESMO Breast Cancer meeting. More information and registration can be found on the ESMO website (https://www.esmo.org/meetings/esmo-breast-cancer-2022).

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se